Stifel’s report offers a deep dive into the latest clinical developments, market dynamics, and pipeline innovations in obesity drugs following the June 2025 ADA conference—with select data contributed by DealForma. Read it here

Nature’s article on biotech’s shifting landscape cites DealForma data showing 2025 venture financing nearing $27B, with more money going to fewer, well-funded startups. Read it here

Stifel’s ASCO 2025 recap and oncology market update, incorporating DealForma data, highlights the rise of bispecific and ADC-based therapies, shifting pharma buyer strategies, and China’s growing prominence in oncology licensing and innovation. Read it here

AI drug discovery deals now feature nine‑figure upfronts and billion‑dollar milestones, with DealForma data showing a shift toward biologics, real‑world data, and broader pharma-AI partnerships. Read it here

CNBC uses data from DealForma to report on Pfizer’s and China’s 3SBio’s deal to license cancer drug. Watch the clip here

Using DealForma insights, PharmaShots’ Top 20 Biopharma Deal Terminations of 2024 highlights major partnership cancellations, led by the $4.45B Adaptimmune–Genentech deal. Read it here

In Q1 2025, J.P. Morgan’s biopharma and medtech deal reports—powered by DealForma—highlighted sustained investor interest with $6.7B in biopharma and $3.7B in medtech venture funding, alongside significant licensing and M&A activity, despite a cautious IPO market. Download their analysis

China’s biotech sector is staging a strong comeback in 2025, driven by a surge in licensing deals, improving fundamentals, and revived investor interest, even as U.S. biotech struggles with political headwinds and regulatory setbacks. Data from DealForma shows Chinese companies now account for 42% of $50M+ licensing deals, highlighting China’s growing role in global biopharma innovation. Read the article here

Despite the XBI’s 27% drop since Trump’s election and widespread market uncertainty, Q1 2025 biotech dealmaking and venture funding showed surprising underlying stability, particularly in licensing, M&A, and Phase 2 asset deals. Data from DealForma highlights the rapid rise of Chinese biotechs, now accounting for 42% of major licensing deals, while Big Pharma continues to prioritize mid-stage assets. Read the article here

Kailera Therapeutics fast-tracked its entry into the obesity drug market by licensing four clinical-stage therapies from China’s Hengrui, reflecting a broader shift as U.S. firms tap China’s growing pharmaceutical innovation. With $400 million in backing and a leadership team built for speed, Kailera aims to outpace competitors by launching a best-in-class injectable and oral GLP-1 pipeline in the high-growth global weight-loss market. Read the article here

The biotech market faced continued pressure last week amid broader macroeconomic and political uncertainty, with investor sentiment remaining weak and capital markets activity slowing. Data, in part from DealForma, highlights ongoing M&A dynamics and a significant surge in licensing deals from Chinese biotechs. Read the article here

Investor interest in gene therapy has declined sharply, with venture funding dropping and some companies like Pfizer pulling back, as attention shifts to higher-growth areas like obesity and cancer. Data from DealForma highlights the steep funding drop, while industry experts point to manufacturing challenges, high costs, and evolving regulatory needs as barriers that must be overcome for a rebound. Read the article here